Efforts made to distinguish MAC from AC at the molecular level may improve on the ability to define each entity, when further stratified by sidedness, to determine the prognostic impact of KRAS and BRAF mutations in the setting of MSI, and to identify other prognostic and predictive molecular markers to develop more specific treatment guidelines for this rare cancer. This evidence concerns the gene BRAF and cancer.